Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to -$122000.0.

  • Utah Medical Products' Exchange Rate Effect fell 13177.08% to -$122000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $48000.0, marking a year-over-year decrease of 8974.36%. This contributed to the annual value of -$677000.0 for FY2024, which is 29970.5% down from last year.
  • As of Q3 2025, Utah Medical Products' Exchange Rate Effect stood at -$122000.0, which was down 13177.08% from $520000.0 recorded in Q2 2025.
  • Over the past 5 years, Utah Medical Products' Exchange Rate Effect peaked at $819000.0 during Q4 2022, and registered a low of -$949000.0 during Q3 2022.
  • For the 5-year period, Utah Medical Products' Exchange Rate Effect averaged around -$40105.3, with its median value being -$11000.0 (2021).
  • Within the past 5 years, the most significant YoY rise in Utah Medical Products' Exchange Rate Effect was 754545.45% (2022), while the steepest drop was 254137.93% (2022).
  • Over the past 5 years, Utah Medical Products' Exchange Rate Effect (Quarter) stood at -$11000.0 in 2021, then soared by 7545.45% to $819000.0 in 2022, then tumbled by 40.42% to $488000.0 in 2023, then plummeted by 234.63% to -$657000.0 in 2024, then soared by 81.43% to -$122000.0 in 2025.
  • Its Exchange Rate Effect stands at -$122000.0 for Q3 2025, versus $520000.0 for Q2 2025 and $307000.0 for Q1 2025.